<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>CSE Tracker</title>
    <link>https://master--youthful-lamport-190a0e.netlify.app/</link>
      <atom:link href="https://master--youthful-lamport-190a0e.netlify.app/index.xml" rel="self" type="application/rss+xml" />
    <description>CSE Tracker</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Sat, 07 Aug 2021 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://master--youthful-lamport-190a0e.netlify.app/images/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_512x512_fill_lanczos_center_2.png</url>
      <title>CSE Tracker</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/</link>
    </image>
    
    <item>
      <title>2021 Joint Statistical Meetings (JSM)</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210807jsm/</link>
      <pubDate>Sat, 07 Aug 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210807jsm/</guid>
      <description>&lt;p&gt;&lt;span style=&#34;color: salmon;&#34;&gt;&lt;em&gt;Registration open: May 3; Early registration Deadline: May 31&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>2021 UW Biostatistics Online Summer Institutes</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/202107072021-uw-biostatistics-online-summer-institutes/</link>
      <pubDate>Wed, 07 Jul 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/202107072021-uw-biostatistics-online-summer-institutes/</guid>
      <description>&lt;p&gt;&lt;span style=&#34;color: salmon;&#34;&gt;&lt;em&gt;Early registration Deadline: Jun 18, 2021&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>DIA 2021 Global Annual Meeting</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210627dia-2021-global-annual-meeting/</link>
      <pubDate>Sun, 27 Jun 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210627dia-2021-global-annual-meeting/</guid>
      <description></description>
    </item>
    
    <item>
      <title>2021 Nonclinical Biostatistics Conference</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/202106212021-nonclinical-biostatistics-conference/</link>
      <pubDate>Mon, 21 Jun 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/202106212021-nonclinical-biostatistics-conference/</guid>
      <description></description>
    </item>
    
    <item>
      <title>PSI 2021 Online Conference</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210621psi-2021-online-conference/</link>
      <pubDate>Mon, 21 Jun 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210621psi-2021-online-conference/</guid>
      <description></description>
    </item>
    
    <item>
      <title>2021 WNAR Annual Meeting</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/202106132021-wnar-annual-meeting/</link>
      <pubDate>Sun, 13 Jun 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/202106132021-wnar-annual-meeting/</guid>
      <description></description>
    </item>
    
    <item>
      <title>2021 Symposium on Data Science &amp; Statistics (SDSS)</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/202106022021-symposium-on-data-science-statistics/</link>
      <pubDate>Wed, 02 Jun 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/202106022021-symposium-on-data-science-statistics/</guid>
      <description>&lt;p&gt;&lt;span style=&#34;color: salmon;&#34;&gt;&lt;em&gt;Early registration Deadline: Apr 7, 2021&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>ISPOR 2021</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210517ispor-2021/</link>
      <pubDate>Mon, 17 May 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210517ispor-2021/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The Statistical Methods in Imaging Conference 2021</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210517the-statistical-methods-in-imaging-conference-2021/</link>
      <pubDate>Mon, 17 May 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210517the-statistical-methods-in-imaging-conference-2021/</guid>
      <description>&lt;p&gt;&lt;span style=&#34;color: salmon;&#34;&gt;&lt;em&gt;Registration ends on May 2, 2021&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>First CANSSI-NISS Health Data Science Workshop</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210506first-canssi-niss-health-data-science-workshop/</link>
      <pubDate>Thu, 06 May 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210506first-canssi-niss-health-data-science-workshop/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The 4th Stat4Onc Annual Symposium (2021)</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210506the-4th-stat4onc-annual-symposium-2021/</link>
      <pubDate>Thu, 06 May 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210506the-4th-stat4onc-annual-symposium-2021/</guid>
      <description>&lt;p&gt;Topics for this symposium include big data and genomics, novel dose-finding designs, umbrella/basket designs, drug combinations, immune-based oncology, and engagement of under-representative population in oncology research.&lt;br&gt;
&lt;span style=&#34;color: salmon;&#34;&gt;&lt;em&gt;Early registration Deadline: Mar 31, 2021&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Oncology and Imunno-Oncology Drug Discovery: from Hit-Finding to Pre-Clinical Candidate Selection</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210504oncology-and-imunno-oncology-drug-discovery-from-hit-finding-to-pre-clinical-candidate-selection/</link>
      <pubDate>Tue, 04 May 2021 08:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210504oncology-and-imunno-oncology-drug-discovery-from-hit-finding-to-pre-clinical-candidate-selection/</guid>
      <description>&lt;p&gt;An expert from Hitgen will discuss the application of DNA-encoded library (DEL) technology: the mechanics of DEL, the advantages and challenges of the technology to those considering DEL technology for identifying ligands for their target of interest.&lt;/p&gt;
&lt;p&gt;An expert from Oncodesign will discuss how patient-derived xenograft (PDX) and PDX-derived models should be incorporated into different stages of the drug discovery process, taking example of Drug Positioning in Breast Cancer with relevant human projection.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>PSI One-Day Meeting: Missing Data in Clinical Trials - Past, Present and Future</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210504psi-one-day-meeting-missing-data-in-clinical-trials-past-present-and-future/</link>
      <pubDate>Tue, 04 May 2021 02:30:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210504psi-one-day-meeting-missing-data-in-clinical-trials-past-present-and-future/</guid>
      <description>&lt;p&gt;Incomplete datasets due to missing data is an issue that has been, and will be, around for a long time. At this meeting we will present the evolution of missing data approaches, looking at how they have been handled in the past, the current established missing data approaches and the impact of the new ICH E9 R1 addendum on the handling of missing data, focussing in particular on the treatment policy estimand.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Competing Frameworks and Methods for Competing Risks Data</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/course/slug/</link>
      <pubDate>Fri, 30 Apr 2021 09:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/course/slug/</guid>
      <description>&lt;p&gt;Competing risks data arise frequently in clinical and epidemiologic studies. Such data are characterized by a survival time that terminates due to one of several mutually exclusive causes. This webinar will cover the following: the two most commonly adopted frameworks for competing risks data; relevant estimands and estimators within each framework; the role of censoring as a competing risk; available modeling strategies; and causal inference in the competing risks setting. The main ideas will be illustrated through several real-data examples.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Communicating Statistics to the Media: Highs and Lows During the Pandemic (so far)</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210429communicating-statistics-to-the-media-highs-and-lows-during-the-pandemic-so-far/</link>
      <pubDate>Thu, 29 Apr 2021 09:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210429communicating-statistics-to-the-media-highs-and-lows-during-the-pandemic-so-far/</guid>
      <description>&lt;p&gt;The current crisis is notable for the vast traffic in official and unofficial information and claims.  I will offer some personal insights into the challenges of trying to bring some illumination to the statistics about the pandemic, illustrated with some examples of things have gone fairly well, and some communication disasters.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>PSI One-Day Meeting: Non-proportional hazards and applications in immuno-oncology</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210429psi-one-day-meeting-non-proportional-hazards-and-applications-in-immuno-oncology/</link>
      <pubDate>Thu, 29 Apr 2021 03:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210429psi-one-day-meeting-non-proportional-hazards-and-applications-in-immuno-oncology/</guid>
      <description>&lt;p&gt;Designs of clinical trials with time to event primary endpoints usually rely on hazards being constant over time. A major challenge in immuno-oncology is the delayed onset of benefit with such therapies and the presence of non-proportional hazards. The impact of this needs to be accounted for in sample size calculations, analysis methodology and reporting. In this meeting we will examine possible strategies to handle such features, which may not be fully known when the trial is initiated.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>PSI VisSIG Webinar: Rapid Insights to Data</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210428psi-vissig-webinar-rapid-insights-to-data/</link>
      <pubDate>Wed, 28 Apr 2021 09:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210428psi-vissig-webinar-rapid-insights-to-data/</guid>
      <description></description>
    </item>
    
    <item>
      <title>DahShu Webinar: Dynamic Data Monitoring of Ongoing Clinical Trials</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210423dynamic-data-monitoring-of-ongoing-clinical-trials/</link>
      <pubDate>Fri, 23 Apr 2021 09:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210423dynamic-data-monitoring-of-ongoing-clinical-trials/</guid>
      <description>&lt;p&gt;According to a recent report, nearly 70% Phase II trials failed to move forward to Phase III. Part of the reasons caused such high failure rate could be inefficient trial design and trial monitoring. In this talk, we introduce the concept of dynamic data monitoring (DDM) for ongoing clinical trials. We develop the principles and procedures for dynamically monitoring on-going clinical trials and demonstrate that the accumulative treatment effect can be automatically estimated and continuously accessible over the information time. Building on the adaptive group sequential (AGS) methods, and by taking the advantage of modern eClinical technologies, we developed a clinical trial “radar” system on which the Wald statistics, conditional power, trend, timing for sample size re-estimation, alerting of early stopping for efficacy and/or futility can be automatically displayed. Thus, the trail can be intelligently monitored. Through simulation, we demonstrate the power of DDM in guiding a promising trial to success or detecting a “hopeless” trial to stop. We provide an example of DDM application in the 1st remdesivir trial in Wuhan China.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>European Causal Inference Meeting (EuroCIM) 2021</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210423european-causal-inference-meeting-eurocim-2021/</link>
      <pubDate>Fri, 23 Apr 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210423european-causal-inference-meeting-eurocim-2021/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Virtual courses (exact times TBD)&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;23 April: &amp;ldquo;Introduction to causal inference&amp;rdquo; by Rhian Daniel (Cardiff University)&lt;br&gt;
18 May: &amp;ldquo;Causal machine learning&amp;rdquo; by Stijn Vansteelandt (Ghent University)&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Events (exact times and ordering of talks for each theme TBD)&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;19 May: Theme 1: Methods (propensity score; double robust &amp;amp; semiparametric estimation; machine learning; Bayesian methods; etc), Invited speaker: Edward Kennedy (Carnegie Mellon University)&lt;/p&gt;
&lt;p&gt;26 May: Theme 2: Survival / longitudinal analyses, trials &amp;amp; estimands, Invited speaker: Jessica Young (Harvard Medical School)&lt;/p&gt;
&lt;p&gt;2 July: Theme 3: Mixed topics - including e.g., applications, designs (IVs etc), interference, econometrics, Invited speaker: Ingeborg Waernbaum (Uppsala University)&lt;/p&gt;
&lt;p&gt;2 September: Theme 4: Foundations, causal DAGs, structural equation models, mediation analysis, Invited speaker: Thomas Richardson (University of Washington)&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Polygenic Risk Prediction and Equitable Disease Prevention</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/course/slug/</link>
      <pubDate>Thu, 22 Apr 2021 11:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/course/slug/</guid>
      <description>&lt;p&gt;Recent discoveries from large scale genome-wide association studies (GWAS) have raised the prospect of using polygenic risk scores in routine health care setting for the prediction of future incidence of large variety of complex diseases. However, as GWAS studies to date have been heavily biased towards European origin populations, current polygenic risk scores often underperform in non-European populations and thus use of them can further exacerbate healthcare inequality. In this talk, I will review simple and advanced statistical methods for generating polygenic risk score using high-dimensional SNP data and describe theoretical characterizations of their expected performance, both in the population that underlies original studies and in a different population that is expected to have different distribution of allele frequencies and linkage disequilibrium (SNP-correlation). I will further describe novel Bayesian and machine learning based methods for building polygenic risk scores that can borrow information across GWAS studies of different ethnic groups, and thus makes best use of available data to generate more powerful polygenic risk scores across different ethnic groups. I will demonstrate potential utility for PRS in precision medicine using our recent studies on breast cancer.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>26th Pfizer/ASA/UConn Distinguished Statistician Colloquium: Four Excursions in Genomics </title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/2021042126th-pfizer-asa-uconn-distinguished-statistician-colloquium-four-excursions-in-genomics/</link>
      <pubDate>Wed, 21 Apr 2021 12:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/2021042126th-pfizer-asa-uconn-distinguished-statistician-colloquium-four-excursions-in-genomics/</guid>
      <description>&lt;p&gt;The purpose of the Colloquium is to provide a forum for a distinguished statistician to share and disseminate their unique perspective and work in the theory and/or application of statistics. This year’s speaker will be Professor Peter Bickel, from the Department of Statistics, University of California, Berkeley. The title of his presentation will be “Four excursions in genomics”.&lt;/p&gt;
&lt;p&gt;The colloquium will be followed by a discussion with Liza Levina from the University of Michigan, Ann Arbor, Purnamrita Sarkar from the University of Texas, Austin, and Rachel Wang, from the University of Sydney.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>NISS-Merck Meet-Up: Open Source Software in Pharma</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210421niss-merck-meet-up-open-source-software-in-pharma/</link>
      <pubDate>Wed, 21 Apr 2021 08:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210421niss-merck-meet-up-open-source-software-in-pharma/</guid>
      <description>&lt;p&gt;Use of open access software, especially R,  is becoming prevalent in pharma. There is a tremendous amount of interest, but many do not understand the basic landscape regarding regulators’ thoughts, the groups that have been working in this area and what has already been accomplished.  This meet-up will discuss this topic from different viewpoints, including an expert from the R Validation Hub (the group that has probably given the deepest thought to this topic), regulatory, and practitioners who have used open access software for submissions in the device field.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Duke Industry Statistics Symposium</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210421duke-industry-statistics-symposium/</link>
      <pubDate>Wed, 21 Apr 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210421duke-industry-statistics-symposium/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Flying the Plane While Improving It - Learning from COVID Patient Data in Close to Real Time</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210415flying-the-plane-while-improving-it-learning-from-covid-patient-data-in-close-to-real-time/</link>
      <pubDate>Thu, 15 Apr 2021 09:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210415flying-the-plane-while-improving-it-learning-from-covid-patient-data-in-close-to-real-time/</guid>
      <description>&lt;p&gt;In the current pandemic the need to translate clinical data into actionable research to inform patient care has never been more urgent. Using the Precision Medicine Analytics Platform at Johns Hopkins University, a team of clinicians, biostatisticians and information technologists at the Precision Medicine Center of Excellence for COVID-19 rapidly created a COVID-19 patient registry and deployed an array of biostatistical methods to understand patient trajectories, conduct comparative effectiveness research for therapeutics, learn about pathobiology of COVID-19 and implement a real-time prediction model into the electronic health record (EHR). Join this session to hear about the lessons learned from conducting research in real time while building a complex data registry.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>DIA/FDA Biostatistics Industry and Regulator Forum</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210414dia-fda-biostatistics-industry-and-regulator-forum/</link>
      <pubDate>Wed, 14 Apr 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210414dia-fda-biostatistics-industry-and-regulator-forum/</guid>
      <description></description>
    </item>
    
    <item>
      <title>13th Annual University of Pennsylvania Conference on Statistical Issues in Clinical Trials</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/2021041213th-annual-university-of-pennsylvania-conference-on-statistical-issues-in-clinical-trials/</link>
      <pubDate>Mon, 12 Apr 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/2021041213th-annual-university-of-pennsylvania-conference-on-statistical-issues-in-clinical-trials/</guid>
      <description></description>
    </item>
    
    <item>
      <title>2021 April BBSW Meetup</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/202104082021-apr-bbsw-meetup/</link>
      <pubDate>Thu, 08 Apr 2021 16:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/202104082021-apr-bbsw-meetup/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Time Series - A First Course with Bootstrap Sampler</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/course/slug/</link>
      <pubDate>Thu, 08 Apr 2021 07:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/course/slug/</guid>
      <description>&lt;p&gt;This course will be a reprise of the main topics of the book by the same name, by Tucker McElroy and Dimitris Politis. The intended audience includes statisticians with little or no knowledge of time series, but a general knowledge of statistics. Prerequisites include a course on linear models, a course on mathematical statistics (such concepts as bias, variance, and the Gaussian distribution), and a familiarity with linear algebra (the transpose, inverse, and eigen-values of a matrix). The aim is to cover basic concepts of time series analysis at a level suitable for those with a bachelor&amp;rsquo;s or master&amp;rsquo;s degree in statistics, while including a few non-standard concepts such as volatility filtering and time series bootstraps. A second aim is to incorporate coding in R of all concepts, methods, and examples.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Causal Inference for Multiple Time-point (Longitudinal) Exposures</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/course/slug/</link>
      <pubDate>Wed, 07 Apr 2021 10:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/course/slug/</guid>
      <description>&lt;p&gt;This workshop applies the Causal Roadmap to estimate the causal effects with multiple intervention variables, such as the cumulative effect of an exposure over time, controlled direct effects, and effects on survival-type outcomes with right-censoring. We will cover longitudinal causal models, identification in the presence of time-dependent confounding; and estimation of joint treatment effects using G-computation, inverse probability weighting (IPW), and targeted maximum likelihood estimation (TMLE) with Super Learner. During the workshop session, participants will work through the Roadmap using an applied example and implement these estimators with the ltmle R package. Prior training in causal inference in a single time-point setting is strongly recommended, but not required.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>A Law of Robustness for Two-layer Neural Networks</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210402a-law-of-robustness-for-two-layer-neural-networks/</link>
      <pubDate>Fri, 02 Apr 2021 08:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210402a-law-of-robustness-for-two-layer-neural-networks/</guid>
      <description></description>
    </item>
    
    <item>
      <title>2021 04 01 </title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/post/2021-04-01-/</link>
      <pubDate>Thu, 01 Apr 2021 12:44:48 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/post/2021-04-01-/</guid>
      <description>
&lt;script src=&#34;./rmarkdown-libs/header-attrs/header-attrs.js&#34;&gt;&lt;/script&gt;
&lt;link href=&#34;./rmarkdown-libs/anchor-sections/anchor-sections.css&#34; rel=&#34;stylesheet&#34; /&gt;
&lt;script src=&#34;./rmarkdown-libs/anchor-sections/anchor-sections.js&#34;&gt;&lt;/script&gt;


</description>
    </item>
    
    <item>
      <title>COPSS-NISS COVID-19 Data Science Webinar Series: Pandemics, Poverty and Public Health</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210401copss-niss-covid-19-data-science-webinar-series-pandemics-poverty-and-public-health/</link>
      <pubDate>Thu, 01 Apr 2021 09:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210401copss-niss-covid-19-data-science-webinar-series-pandemics-poverty-and-public-health/</guid>
      <description>&lt;p&gt;This presentation will focus on Dr. Kim’s 30 years of experience in battling a pandemics in developing countries.  A trained infectious disease physician, Dr. Kim has tackled multidrug-resistant tuberculosis, HIV, cholera, Ebola and now COVID-19 in developing countries in Latin America, Asia and Africa.  He has also been involved in the COVID-19 response in the United States through the organization he co-founded, Partners in Health.  Dr. Kim will first talk about his experiences in combatting both poverty and infectious diseases throughout his career and then looks forward to a robust question and answer session.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Sharp Inference on Selected Subgroups in Observational Studies</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210401sharp-inference-on-selected-subgroups-in-observational-studies/</link>
      <pubDate>Thu, 01 Apr 2021 08:30:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210401sharp-inference-on-selected-subgroups-in-observational-studies/</guid>
      <description>&lt;p&gt;In modern drug development, the broader availability of high-dimensional observational data provides opportunities for scientist to explore subgroup heterogeneity, especially when randomized clinical trials are unavailable due to cost and ethical constraints. However, a common practice that naively searches the subgroup with a high treatment level is often misleading due to the “subgroup selection bias.” More importantly, the nature of high-dimensional observational data has further exacerbated the challenge of accurately estimating the subgroup treatment effects. To resolve these issues, we provide new inferential tools based on resampling to assess the replicability of post-hoc identified subgroups from observational studies. Through careful theoretical justification and extensive simulations, we show that our proposed approach delivers asymptotically sharp confidence intervals and debiased estimates for the selected subgroup treatment effects in the presence of high-dimensional covariates. We further demonstrate the merit of the proposed methods by analyzing the UK Biobank data. The R package “debiased.subgroup&amp;quot; implementing the proposed procedures is available on GitHub.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title> ASA Biopharm&#39;s Podcast</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Thu, 01 Apr 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Practical Significance Podcast</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Thu, 01 Apr 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Stats &#43; Stories Podcast</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Thu, 01 Apr 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The Pod of Asclepius</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Thu, 01 Apr 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Duke-Margolis Seminars</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Fri, 26 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Foundations of Data Science - Virtual Talk Series</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Fri, 26 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>International Seminar on Selective Inference</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Fri, 26 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>National Institute of Statistical Sciences (NISS) Meeting Recordings</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Fri, 26 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Neural Information Processing Systems (NeurIPS) Video Archives</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Fri, 26 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Online Causal Inference Seminar</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Fri, 26 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Online Seminar on  Mathematical Foundations of Data Science</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Fri, 26 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Royal Statistical Society (RSS) Video and Audio</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Fri, 26 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Royal Statistical Society (RSS) Webinars</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Fri, 26 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>RStudio webinars</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Fri, 26 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Statisticians in the Pharmaceutical Industry (PSI) Video-on-Demand</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</link>
      <pubDate>Fri, 26 Mar 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/resource/slug/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Designing a Randomized Trial with Sample Size Re-estimation - Challenges and Best Practices</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210325designing-a-randomized-trial-with-sample-size-re-estimation-challenges-and-best-practices/</link>
      <pubDate>Thu, 25 Mar 2021 09:00:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210325designing-a-randomized-trial-with-sample-size-re-estimation-challenges-and-best-practices/</guid>
      <description>&lt;p&gt;In this webinar, we will play the part of a sponsor consulting a statistician with the goal of designing a randomized trial with sample-size re-estimation. We will discuss the concept of conditional power and the promising-zone method, and we will present a pragmatic view of some issues, including when to plan the sample-size re-estimation in the course of the accrual, how to select the amount of sample-size increase, and how to operate such trials in practice. We will also discuss the pros- and cons- of using this type of design in relation to the clinical setting in which the trial is designed and endpoints it uses. Moreover, we will discuss the regulators’ views and illustrate our discussion with practical examples.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Synthetic Control Mythbusters</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210325synthetic-control-mythbusters/</link>
      <pubDate>Thu, 25 Mar 2021 08:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210325synthetic-control-mythbusters/</guid>
      <description>&lt;p&gt;Synthetic control arms leverage real world data from various sources or evaluations of historical clinical data to demonstrate the positive effects of a new therapy or treatment, without the need to use a placebo or standard of care as a control.&lt;/p&gt;
&lt;p&gt;Regulators in both the United States and Europe have responded positively to the use of SCAs in clinical development. While implementation of this method for regulatory purposes might be a new development, the majority of statistical and mathematical theories used for the design of SCAs are decades old and familiar to the scientific community. However, synthetic control arm studies are often subject to many misplaced industry myths.&lt;/p&gt;
&lt;p&gt;During this webinar our panel of expert speakers from Cytel, Roche and CIOX Health, will share their insights and bust Real-World Data industry myths around the use of synthetic controls in research and regulatory applications. In addition, they will dispel and bust a number of myths related to their specific sector of industry, namely pharma, data vendor, and consulting.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Learning from COVID-19 Data on Transmission, Health Outcomes, Interventions and Vaccination </title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210323learning-from-covid-19-data-on-transmission-health-outcomes-interventions-and-vaccination/</link>
      <pubDate>Tue, 23 Mar 2021 12:00:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210323learning-from-covid-19-data-on-transmission-health-outcomes-interventions-and-vaccination/</guid>
      <description>&lt;p&gt;Video Passcode &lt;span style=&#34;color: green;&#34;&gt;&lt;em&gt;=TpGiw#6&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Registration&lt;/strong&gt;: &lt;br&gt;
ASA Members: $20&lt;br&gt;
Student ASA Member: $15&lt;br&gt;
Nonmembers: $35&lt;/p&gt;
&lt;p&gt;In this talk, I will first provide a historical overview of the epidemic in Wuhan. I will then provide the analysis results of 32,000 lab-confirmed COVID-19 cases in Wuhan to estimate the transmission rates using Poisson Partial Differential Equation based transmission dynamic models. This model is also used to evaluate the effects of different public health interventions on controlling the COVID-19 outbreak, such as social distancing, isolation and quarantine. I will present the results on the epidemiological characteristics of the cases. The results show that multi-faceted intervention measures successfully controlled the outbreak in Wuhan. I will next present transmission regression models for estimating transmission rates in USA and other countries, as well as factors including intervention effects using social distancing, test-trace-isolate strategies that affect transmission rates. I will discuss estimation of the proportion of undetected cases, including asymptomatic, pre-symptomatic cases and mildly symptomatic cases, the chances of resurgence in different scenarios, prevalence, and the factors that affect transmissions. I will also present the US county-level analysis to study the demographic, social-economic, and comorbidity factors that are associated with COVID-19 case and death rates. I will also present the analysis results of &amp;gt;500,000 participants of the HowWeFeel project on health outcomes and behaviors in US, and discuss the factors associated with infection, behavior, and vaccine hesitancy. I will provide several takeaways and discuss priorities.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>General Framework for Optimal Data-Driven Optimization</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210319general-framework-for-optimal-data-driven-optimization/</link>
      <pubDate>Fri, 19 Mar 2021 08:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210319general-framework-for-optimal-data-driven-optimization/</guid>
      <description>&lt;p&gt;We propose a statistically optimal approach to construct data-driven decisions for stochastic optimization problems. Fundamentally, a data-driven decision is simply a function that maps the available training data to a feasible action. It can always be expressed as the minimizer of a surrogate optimization model constructed from the data. The quality of a data-driven decision is measured by its out-of-sample risk. An additional quality measure is its out-of-sample disappointment, which we define as the probability that the out-of-sample risk exceeds the optimal value of the surrogate optimization model. The crux of data-driven optimization is that the data-generating probability measure is unknown. An ideal data-driven decision should therefore minimize the out-of-sample risk simultaneously with respect to every conceivable probability measure (and thus in particular with respect to the unknown true measure). Unfortunately, such ideal data-driven decisions are generally unavailable. This prompts us to seek data-driven decisions that minimize the out-of-sample risk subject to an upper bound on the out-of-sample disappointment - again simultaneously with respect to every conceivable probability measure. We prove that such Pareto-dominant data-driven decisions exist under conditions that allow for interesting applications: the unknown data-generating probability measure must belong to a parametric ambiguity set, and the corresponding parameters must admit a sufficient statistic that satisfies a large deviation principle. If these conditions hold, we can further prove that the surrogate optimization model generating the optimal data-driven decision must be a distributionally robust optimization problem constructed from the sufficient statistic and the rate function of its large deviation principle. This shows that the optimal method for mapping data to decisions is, in a rigorous statistical sense, to solve a distributionally robust optimization model. Maybe surprisingly, this result holds irrespective of whether the original stochastic optimization problem is convex or not and holds even when the training data is non-i.i.d. As a byproduct, our analysis reveals how the structural properties of the data-generating stochastic process impact the shape of the ambiguity set underlying the optimal distributionally robust optimization model. This is joint work with Tobias Sutter and Bart Van Parys.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Deciphering Neural Networks through the Lens of Feature Interactions</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210226deciphering-neural-networks-through-the-lens-of-feature-interactions/</link>
      <pubDate>Fri, 26 Feb 2021 12:00:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210226deciphering-neural-networks-through-the-lens-of-feature-interactions/</guid>
      <description>&lt;p&gt;Interpreting how neural networks work is a crucial and challenging task in machine learning. In this talk, I will discuss a novel framework, namely neural interaction detector (NID), for interpreting complex neural networks by detecting statistical interactions captured by the neural networks. Furthermore, we can construct a more interpretable generalized additive model that achieve similar prediction performance as the original neural networks. Experiment results on several applications, such as recommender systems, image recognition, sentiment prediction, demonstrate the effectiveness of NID.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Veridical Data Science for biomedical discovery: detecting epistatic interactions with epiTree</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210226veridical-data-science-for-biomedical-discovery-detecting-epistatic-interactions-with-epitree/</link>
      <pubDate>Fri, 26 Feb 2021 09:30:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210226veridical-data-science-for-biomedical-discovery-detecting-epistatic-interactions-with-epitree/</guid>
      <description>&lt;p&gt;Data Science is a pillar of A.I. and has driven most of recent cutting-edge discoveries in biomedical research. In practice, Data Science has a life cycle (DSLC) that includes problem formulation, data collection, data cleaning, modeling, result interpretation and the drawing of conclusions. Human judgement calls are ubiquitous at every step of this process, e.g., in choosing data cleaning methods, predictive algorithms and data perturbations. Such judgment calls are often responsible for the &amp;ldquo;dangers&amp;rdquo; of A.I. To maximally mitigate these dangers, we developed a framework based on three core principles: Predictability, Computability and Stability (PCS). Through a workflow and documentation (in R Markdown or Jupyter Notebook) that allows one to manage the whole DSLC, the PCS framework unifies, streamlines and expands on the best practices of machine learning and statistics - bringing us a step forward towards veridical Data Science.&lt;/p&gt;
&lt;p&gt;In this lecture, we will illustrate the PCS framework through the epiTree; a pipeline to discover epistasis interactions from genomics data. epiTree addresses issues of scaling of penetrance through decision trees, significance calling through PCS p-values, and combinatorial search over interactions through iterative random forests (which is a special case of PCS). Using UK Biobank data, we validate the epiTree pipeline through an application to the red-hair phenotype, where several genes are known to display epistatic interactions.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>The Role of a Statistician</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210226the-role-of-a-statistician/</link>
      <pubDate>Fri, 26 Feb 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210226the-role-of-a-statistician/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Illuminating the Black Box: Variable Importance Measures for Interpretable Machine Learning</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210225illuminating-the-black-box-variable-importance-measures-for-interpretable-machine-learning/</link>
      <pubDate>Thu, 25 Feb 2021 11:00:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210225illuminating-the-black-box-variable-importance-measures-for-interpretable-machine-learning/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Recording passcode&lt;/strong&gt;: 6cleDgX+&lt;/p&gt;
&lt;p&gt;In this talk, Dr. Wolf will provide an overview of common machine learning methods (e.g. ensemble methods, support vector machines and neural networks) and discuss currently implemented importance measures that provide semi-quantitative measures of associations between variables and outcome.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>2021 ASA Conference on Statistical Practice</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20210217csp/</link>
      <pubDate>Wed, 17 Feb 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20210217csp/</guid>
      <description>&lt;p&gt;The goal of the conference is to provide participants with opportunities to learn new statistical methodologies and best practices in statistical analysis, design, consulting, and statistical programming.&lt;br&gt;
&lt;span style=&#34;color: salmon;&#34;&gt;&lt;em&gt;Early registration Deadline: Jan 11, 2021&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Bias and Randomization 1980 - 2020 - 2060</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210211bias-and-randomization-1980-2020-2060/</link>
      <pubDate>Thu, 11 Feb 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210211bias-and-randomization-1980-2020-2060/</guid>
      <description>&lt;p&gt;Learn on history of bias and randomization in oncology clinical trials and how to think about what constitutes persuasive evidence of treatment efficacy and safety.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>PIONEERing estimands in Clinical Research</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210112pioneering-estimands-in-clinical-research/</link>
      <pubDate>Tue, 12 Jan 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210112pioneering-estimands-in-clinical-research/</guid>
      <description>&lt;p&gt;Bringing estimands to life through a real case study. A year on after the final ICH E9 estimands addendum was published, we bring estimands to life from a real example from protocol to press release. Members of the estimands Implementation Working Group (EIWG) will describe the background and study objectives, intercurrent events of interest and chosen estimands in the PIONEER study.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Non-Randomized Studies and Utilization of Real-World Evidence</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201217non-randomized-studies-and-utilization-of-real-world-evidence/</link>
      <pubDate>Thu, 17 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201217non-randomized-studies-and-utilization-of-real-world-evidence/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Data Monitoring and Adaptive Designs</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201215data-monitoring-and-adaptive-designs/</link>
      <pubDate>Tue, 15 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201215data-monitoring-and-adaptive-designs/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Interpretable Machine Learning &amp; Causal Inference Workshop</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201215interpretable-machine-learning-causal-inference-workshop/</link>
      <pubDate>Tue, 15 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201215interpretable-machine-learning-causal-inference-workshop/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;Table 2 Fallacy: Or why interpretation needs more than transparency (Peter Tennant)&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Using causal machine learning to explore heterogeneous responses to policies (Noemi Kreif)&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Symbolic machine learning for interpretable AI: recent advancements and future directions (Alessandra Russo)&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Questioning the AI: towards human-centered interpretable machine learning (Vera Liao)&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>This year&#39;s most popular clinical trial designs topics</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201215this-year-s-most-popular-clinical-trial-designs-topics/</link>
      <pubDate>Tue, 15 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201215this-year-s-most-popular-clinical-trial-designs-topics/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;Phase II Adaptive Trials Designs&lt;/li&gt;
&lt;li&gt;Phase III Adaptive Trial Designs&lt;/li&gt;
&lt;li&gt;Further Webinar Highlights&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Statistical Observations on SARS-CoV-2 and Crisis Vaccine Clinical Testing</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201210statistical-observations-on-sars-cov-2-and-crisis-vaccine-clinical-testing/</link>
      <pubDate>Thu, 10 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201210statistical-observations-on-sars-cov-2-and-crisis-vaccine-clinical-testing/</guid>
      <description>&lt;p&gt;Traditional vaccine clinical development is an undertaking involving meticulous, multiple studies in multiple populations at risk of infection and disease over multiple years. SARS-CoV-2 and COVID-19 vaccine development is following this traditional development pathway, but accelerated Phase I-II-III clinical programs are being applied (c.f., USA FDA guidances 2020). This is not the first time vaccines have been manufactured and tested quickly to meet a public health crisis (1976, 2009). Selected statistical concepts pertaining to vaccine efficacy and safety, relevant during the design and implementation of such crisis programs, are discussed.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Causal reasoning in survival and time-to-event analyses</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201204causal-reasoning-in-survival-and-time-to-event-analyses/</link>
      <pubDate>Fri, 04 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201204causal-reasoning-in-survival-and-time-to-event-analyses/</guid>
      <description></description>
    </item>
    
    <item>
      <title>COPSS-NISS COVID-19 Data Science Webinar Series</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201203copss-niss-covid-19-data-science-webinar-series/</link>
      <pubDate>Thu, 03 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201203copss-niss-covid-19-data-science-webinar-series/</guid>
      <description>&lt;p&gt;The COPSS-NISS COVID-19 Data Science webinar series is co-organized by the Committee of the Presidents of Statistical Societies (COPSS) and its five charter member societies (ASA, ENAR, IMS, SSC, and WNAR), as well as NISS.  This twice a month webinar (1st and 3rd Thursday at noon EST) features the latest research that is positioned on the cusp of new understanding and analysis of COVID-19 pandemic data and promotes data-driven research and decision making to combat COVID-19.&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;April 29, 2021&lt;/strong&gt; Communicating Statistics to the Media: Highs and Lows During the Pandemic&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;April 15, 2021&lt;/strong&gt; Flying the Plane while Improving It – Learning from COVID Patient Data in Close to Real Time&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;April 1, 2021&lt;/strong&gt; Jim Yong Kim, M.D., PhD, Vice Chairman and Partner at Global Infrastructure Partners&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;March 18, 2021&lt;/strong&gt; COVID-19 One Year In: Navigating the Communications Triangle of Experts, Policy Makers, and the Public&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;March 4, 2021&lt;/strong&gt; Predictions, Role of Interventions and the Crisis of Virus in India: A Data Science Call to Arms&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;February 18, 2021&lt;/strong&gt; Misinformation and Attitude Formation Analyzed Through Social Media Posts&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;February 4, 2021&lt;/strong&gt; Insights into Host and Viral Genetics of SARS-CoV-2 Discussed&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;January 21, 2021&lt;/strong&gt; Modeling Frameworks Provide Foundation for Inference and Projection of SARS-CoV-2&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;January 7, 2021&lt;/strong&gt; Epidemiologic Modeling in the Spotlight in 3rd COPSS-NISS COVID-19 Webinar&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;December 17, 2020&lt;/strong&gt; COPSS-NISS Webinar: Delphi’s COVIDcast Project Featured&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;December 3, 2020&lt;/strong&gt; Inaugural COPSS-NISS Webinar on the Statistics of COVID-19 Vaccine Trials - ‘Standing Room Only’!&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Head to Head Comparisons Using Real World Data - Practical Application</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201202head-to-head-comparisons-using-real-world-data-practical-application/</link>
      <pubDate>Wed, 02 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201202head-to-head-comparisons-using-real-world-data-practical-application/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Why Data Science in the Cloud?</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201202why-data-science-in-the-cloud/</link>
      <pubDate>Wed, 02 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201202why-data-science-in-the-cloud/</guid>
      <description></description>
    </item>
    
    <item>
      <title>How to Present Your Research? - Focus and Intentionality Are Keys!</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201130how-to-present-your-research-focus-and-intentionality-are-keys/</link>
      <pubDate>Mon, 30 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201130how-to-present-your-research-focus-and-intentionality-are-keys/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Propensity score weighting for covariate adjustment in randomized clinical trials</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201124propensity-score-weighting-for-covariate-adjustment-in-randomized-clinical-trials/</link>
      <pubDate>Tue, 24 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201124propensity-score-weighting-for-covariate-adjustment-in-randomized-clinical-trials/</guid>
      <description></description>
    </item>
    
    <item>
      <title>U-Design: SaaS for Streamlining Trial Simulation and Report Writing Using Efficient Statistical Designs</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201124u-design-saas-for-streamlining-trial-simulation-and-report-writing-using-efficient-statistical-designs/</link>
      <pubDate>Tue, 24 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201124u-design-saas-for-streamlining-trial-simulation-and-report-writing-using-efficient-statistical-designs/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Clinical Trial Design and Decision Making in a Broader Context - Program and Portfolio Optimization</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201118clinical-trial-design-and-decision-making-in-a-broader-context-program-and-portfolio-optimization/</link>
      <pubDate>Wed, 18 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201118clinical-trial-design-and-decision-making-in-a-broader-context-program-and-portfolio-optimization/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Interview with Judea Pearl</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201117interview-with-judea-pearl/</link>
      <pubDate>Tue, 17 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201117interview-with-judea-pearl/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Predicting Disease Risk from Genomics Data</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201117predicting-disease-risk-from-genomics-data/</link>
      <pubDate>Tue, 17 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201117predicting-disease-risk-from-genomics-data/</guid>
      <description></description>
    </item>
    
    <item>
      <title>PSI Journal Club: Bayesian Methods</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201117psi-journal-club-bayesian-methods/</link>
      <pubDate>Tue, 17 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201117psi-journal-club-bayesian-methods/</guid>
      <description>&lt;p&gt;&lt;span style=&#34;color: green;&#34;&gt;&lt;em&gt;Replay links available on website&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;A Bayesian approach in design and analysis of pediatric cancer clinical trials&lt;/strong&gt;&lt;br&gt;
Speaker: Jingjing Ye (BeiGene)&lt;br&gt;
Publication: Jingjing Ye, Gregory Reaman, R. Angelo De Claro &amp;amp; Rajeshwari Sridhara, Pharmaceutical Statistics. 2020;1–13.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Estimation of group means using Bayesian generalized linear mixed models&lt;/strong&gt;&lt;br&gt;
Speaker: Amy LaLonde (Eli Lilly)&lt;br&gt;
Publication: Amy LaLonde &amp;amp; Yongming Qu, Pharmaceutical Statistics. 2020;19:482–491&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>The Impact of COVID-19 in Clinical Trials</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201117the-impact-of-covid-19-in-clinical-trials/</link>
      <pubDate>Tue, 17 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201117the-impact-of-covid-19-in-clinical-trials/</guid>
      <description>&lt;p&gt;Understanding the Impact of Covid-19 in the areas of:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Clinical Operations&lt;/li&gt;
&lt;li&gt;Data&lt;/li&gt;
&lt;li&gt;Statistical Perspective&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;Composite Intercurrent Events vs ICE Categories&lt;/p&gt;
&lt;p&gt;Statistical Covid-19 strategies including:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Study Design&lt;/li&gt;
&lt;li&gt;Reporting&lt;/li&gt;
&lt;li&gt;Measuring the effect&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Innovations in Bayesian Trials Virtual Symposium</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20201108innovations-in-bayesian-trials-virtual-symposium/</link>
      <pubDate>Sun, 08 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20201108innovations-in-bayesian-trials-virtual-symposium/</guid>
      <description>&lt;p&gt;This dynamic program will cover a range of topics presented by Bayesian experts in academia, regulatory and industry. The presentations will include: Adaptive design, platform studies, complex innovative designs using Bayesian modeling; Regulatory acceptability of Bayesian designs; Leveraging external information using Bayesian priors.&lt;br&gt;
&lt;span style=&#34;color: green;&#34;&gt;&lt;em&gt;Replay links available&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday, October 8, 2020&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Bayesian Statistics and FDA Regulatory Acceptability&lt;/strong&gt;&lt;br&gt;
Greg Campbell, PhD, President, GCStat Consulting (1hr)&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2691488&amp;amp;sessionid=1&amp;amp;key=7C84CEA899224E2CDE4F7E22CFABDECB&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday, October 22, 2020&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Bayesian Dose-finding Designs for Modern Drug Development&lt;/strong&gt;&lt;br&gt;
Yuan Ji, Professor of Biostatistics, Department of Public Health Sciences, The University of Chicago (1hr)&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2691496&amp;amp;sessionid=1&amp;amp;key=08500FE422DAFE88617C8485AB42E961&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday, Novermber 05, 2020&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Bayesian Dynamic Borrowing for Partial Extrapolation and Bridging Studies: Methods and Case Studies&lt;/strong&gt;&lt;br&gt;
Nicky Best, Head, Advanced Biostatistics and Data Analytics Centre of Excellence, GSK (1hr)&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;loginemail=peiwen.wu%40gilead.com&amp;amp;eventid=2691499&amp;amp;sessionid=1&amp;amp;key=3C8FF73C92BC880B2A5989FDE9074FF5&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday, November 19, 2020&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Statistical Design and Conduct of Platform Trials&lt;/strong&gt;&lt;br&gt;
Jason Connor, President &amp;amp; Lead Statistical Scientist, ConfluenceStat (1hr)&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2691515&amp;amp;sessionid=1&amp;amp;key=4B07CFCA81196A4A8DDB075F8E813266&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday, December 3, 2020&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Bayesian Models for Precision Oncology Clinical Trials&lt;/strong&gt;&lt;br&gt;
Peter Mueller, Professor, Department of Mathematics and the
Department of Statistics &amp;amp; Data Science, The University of Texas at Austin (1hr)&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2691509&amp;amp;sessionid=1&amp;amp;key=7B1DA30C7762FC9B3DB4A0EABBE36DD9&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday, December 10, 2020&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Recent Development on Bayesian Clinical Trial Designs Using Historical Data&lt;/strong&gt;&lt;br&gt;
Ming-Hui Chen, Professor and Head of the Department of Statistics, The University of Connecticut (1hr) 
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2691518&amp;amp;sessionid=1&amp;amp;key=B3CA28FA4552CAB13C45A32C412748AD&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;em&gt;&lt;strong&gt;Thursday March 11, 2021&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;Leveraging external evidence in medical device decision-making&lt;/strong&gt;&lt;br&gt;
Ram C. Tiwari, Ph.D. Head of Statistical Methodology, Bristol Myers Squibb&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=3024363&amp;amp;sessionid=1&amp;amp;key=BD2CA3B8AB7D9856260F5287B7FE45B3&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Joint PSI, EFSPI &amp; ASA BIOP Webinar: Estimands</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201105joint-psi-efspi-asa-biop-webinar-estimands/</link>
      <pubDate>Thu, 05 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201105joint-psi-efspi-asa-biop-webinar-estimands/</guid>
      <description>&lt;p&gt;The following aspects are covered:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Experience with proposals submitted to FDA and EMA on implementation of Estimands&lt;/li&gt;
&lt;li&gt;How the estimands framework facilitates interaction with clinicians in different therapeutic areas&lt;/li&gt;
&lt;li&gt;Common problems where the Estimands framework can help advance research&lt;/li&gt;
&lt;li&gt;Where further discussions and research is required, and particularly where industry and regulators can collaborate&lt;/li&gt;
&lt;li&gt;Issues related to alignment between different estimators to a given estimand&lt;/li&gt;
&lt;li&gt;Special considerations of estimand framework in COVID-19 vaccine trials&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Re-imagining Clinical Trials: An Advanced Design Framework for the Era of Cloud-Computing</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201104re-imagining-clinical-trials-an-advanced-design-framework-for-the-era-of-cloud-computing/</link>
      <pubDate>Wed, 04 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201104re-imagining-clinical-trials-an-advanced-design-framework-for-the-era-of-cloud-computing/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Interview with Donald Rubin</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201103interview-with-donald-rubin/</link>
      <pubDate>Tue, 03 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201103interview-with-donald-rubin/</guid>
      <description></description>
    </item>
    
    <item>
      <title>2020 New England Rare Disease Statistics (NERDS) Webinar Series</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/202011022020-new-england-rare-disease-statistics-nerds-webinar-series/</link>
      <pubDate>Mon, 02 Nov 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/202011022020-new-england-rare-disease-statistics-nerds-webinar-series/</guid>
      <description>&lt;p&gt;&lt;strong&gt;1. Introductory NERDS Session&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;How to Select Endpoints and Quantify Treatment Effect in a Comparative Clinical Study on COVID-19 Diseases (L.J. Wei (Harvard))&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Borrowing Information from Historical Data: A Double-edged Sword (Ying Yuan (MD Anderson))&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;a href=&#34;https://pfizerevents.webex.com/pfizerevents/lsr.php?RCID=13985dd6a939e0e4f8998620b4a428b1&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Recording&lt;/a&gt; (Password: hWFURkY5)&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;2. CID Program Update&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;A Bayesian Adaptive Trial in Duchenne Muscular Dystrophy (Steve Lake (Wave Life Sciences))&lt;/li&gt;
&lt;li&gt;Innovative Designs in the Rare Disease Setting (Dionne Price (FDA))&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://pfizerevents.webex.com/pfizerevents/lsr.php?RCID=1bc6e1d02b1002d62c170a17473e3d54&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Recording&lt;/a&gt; (Password: pMbpsJT7)&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;3. Gene Therapy in Rare Disease Development&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Gene Therapy: Opportunities and Challenges for the Treatment of Hemophilia (Michelle Casey (Pfizer))&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://pfizerevents.webex.com/pfizerevents/lsr.php?RCID=ccaaeefdd89e63e72892e9650397f117&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Recording&lt;/a&gt; (Password: NERDS456)&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;4. Case Studies in Rare Disease Drug Development&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Lessons from Notable New Drug Application involving External Controls (Margaret (Meg) Gamalo (Pfizer))&lt;/li&gt;
&lt;li&gt;Design and Analysis of Drop the Losers Studies in the Rare Disease Setting (Glen Laird (Vertex))&lt;/li&gt;
&lt;li&gt;A Case Study Using Nature History Data to Understand Long Term Disease Progression (Cindy Lu (Biogen))&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;https://pfizerevents.webex.com/pfizerevents/lsr.php?RCID=e227bbfd8699459593dffc5ce07cd795&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Recording&lt;/a&gt; (Password: Pq8pBWgU)&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Three Rs - Reliability, Reproducibility, Replicability: The Interplay Between Statistical Science and Data Science</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201030three-rs-reliability-reproducibility-replicability-the-interplay-between-statistical-science-and-data-science/</link>
      <pubDate>Fri, 30 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201030three-rs-reliability-reproducibility-replicability-the-interplay-between-statistical-science-and-data-science/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Clinical Trials for, and despite, COVID-19</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201027clinical-trials-for-and-despite-covid-19/</link>
      <pubDate>Tue, 27 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201027clinical-trials-for-and-despite-covid-19/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;the key characteristics of COVID-19 trials, particularly with regard to trial-design features such as trial mechanics (including factorial and multi-stage designs, as well as platform trials), outcome assessment, and other important methodological issues.&lt;/li&gt;
&lt;li&gt;the impact the pandemic is having on clinical trials in several fields, including oncology and cardiology.&lt;/li&gt;
&lt;li&gt;practical issues pertaining to trial design and conduct, including for data capture, data management, statistical analysis, and patient follow-up, all of which affected by the current crisis.&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Biomarker Analysis in Clinical Trials Using R</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201021biomarker-analysis-in-clinical-trials-using-r/</link>
      <pubDate>Wed, 21 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201021biomarker-analysis-in-clinical-trials-using-r/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Study Design For Non inferiority And Equivalence</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201021study-design-for-non-inferiority-and-equivalence/</link>
      <pubDate>Wed, 21 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201021study-design-for-non-inferiority-and-equivalence/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;Regulatory information on this type of study design&lt;/li&gt;
&lt;li&gt;Considerations for study design and your sample size&lt;/li&gt;
&lt;li&gt;Practical worked examples of Non-inferiority Testing&lt;/li&gt;
&lt;li&gt;Equivalence Testing&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Innovations in Bayesian Clinical Trials Interactive Workshops</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201015innovations-in-bayesian-clinical-trials-interactive-workshops/</link>
      <pubDate>Thu, 15 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201015innovations-in-bayesian-clinical-trials-interactive-workshops/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Interactive Workshop 1: Essentials of Bayesian Statistics&lt;/strong&gt;&lt;br&gt;
October 15, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;loginemail=peiwen.wu%40gilead.com&amp;amp;eventid=2691551&amp;amp;sessionid=1&amp;amp;key=109B6B88F22396785524BCAD42C50522&amp;amp;regTag=&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Interactive Workshop 2: Bayesian Meta-Analysis and Hierarchical Models&lt;/strong&gt;&lt;br&gt;
October 29, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;loginemail=peiwen.wu%40gilead.com&amp;amp;eventid=2691558&amp;amp;sessionid=1&amp;amp;key=8543F409BD3894D06579F92276808A5D&amp;amp;regTag=&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Interactive Workshop 3: Prior Distributions (Part I)&lt;/strong&gt;&lt;br&gt;
November 12, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;loginemail=peiwen.wu%40gilead.com&amp;amp;eventid=2691561&amp;amp;sessionid=1&amp;amp;key=238DEB3AC5D91E14B89095AF22C63D05&amp;amp;regTag=&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Statistical Topics on COVID-19 vaccine and therapeutic clinical trials</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201015statistical-topics-on-covid-19-vaccine-and-therapeutic-clinical-trials/</link>
      <pubDate>Thu, 15 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201015statistical-topics-on-covid-19-vaccine-and-therapeutic-clinical-trials/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Statisticians Debate Issues Central to Inference and Estimation</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201015statisticians-debate-issues-central-to-inference-and-estimation/</link>
      <pubDate>Thu, 15 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201015statisticians-debate-issues-central-to-inference-and-estimation/</guid>
      <description>&lt;p&gt;The purpose of this event was to shed light on and explain the main features (pro and con) that surround some of the controversies on use of p-values.&lt;/p&gt;
&lt;p&gt;Jim Berger (Duke University) has been exploring the Bayesian and frequentist foundations of statistics for 50 years, and has recently been heavily involved in bringing these foundational perspectives to the p-value debate. David Trafimow (New Mexico State University) started the serious questioning of any use of p-values via the journal he edits, and Deborah Mayo (Virginia Tech) has developed a reformulation of frequentist error statistical methods within a full-blown philosophy of learning from error.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>12th Annual Sentinel Initiative Public Workshop</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/2020101412th-annual-sentinel-initiative-public-workshop/</link>
      <pubDate>Wed, 14 Oct 2020 10:00:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/2020101412th-annual-sentinel-initiative-public-workshop/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Session I: A Robust Sentinel System for the 21st Century&lt;/strong&gt;&lt;br&gt;
Objective: In response to new legislative mandates and the desire to diversify scientific expertise and enhance core key capabilities in the Sentinel System, the Center for Drug Evaluation and Research (CDER) has awarded a new five-year contract that establishes a new organizational structure for the Sentinel Coordinating Center. This new contract builds on FDA successes integrating the active, post-market safety surveillance into regulatory decision-making. This session will feature key leads from each Sentinel coordinating center who will discuss plans on how to advance and transform Sentinel’s data infrastructure into a national resource for evidence generation. Panelists will also discuss opportunities for collaboration to broaden stakeholder involvement, improve access to new data sources and analytic tools, and ensure more efficient and effective safety surveillance activities.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Session II: Building the BEST Network and Establishing New Capabilities for the Surveillance of Biologics&lt;/strong&gt;&lt;br&gt;
Objective: Launched in 2017, the BEST Initiative enacts the Agency’s mandate to implement active surveillance for biologic products. This session will highlight key achievements of BEST over the last year enhancing its capabilities to execute safety and effectiveness surveillance and inform regulatory decision making. CBER representatives will discuss ongoing work to support the expansion of the BEST data network and methods infrastructure as well as specific studies utilizing the infrastructure.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Session III: Leveraging the Sentinel Initiative for COVID-19&lt;/strong&gt;&lt;br&gt;
Objective: The U.S. FDA’s Sentinel Initiative is engaged in numerous activities to protect and promote public health during the COVID-19 pandemic. This session will highlight key ongoing efforts across CDER and CBER to leverage Sentinel data infrastructure to describe course of illness, and evaluate the utilization, safety, and effectiveness of available COVID-19 therapeutics and vaccines under real-world conditions.&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>12th Annual Sentinel Initiative Public Workshop</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/2020101412th-annual-sentinel-initiative-public-workshop/</link>
      <pubDate>Wed, 14 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/2020101412th-annual-sentinel-initiative-public-workshop/</guid>
      <description>&lt;p&gt;The Sentinel Initiative, an active medical product surveillance system, was established in response to the Food and Drug Administration (FDA) Amendments Act of 2007 and has become one of the Agency’s premier evidence generation platforms. The 12th Annual Sentinel Initiative Public Workshop is being convened on October 14, 2020 by the Robert J. Margolis, MD, Center for Health Policy under a cooperative agreement with the FDA. The workshop will be held as a virtual webinar and provides an opportunity to discuss recent achievements and developments and engage with the broader community of patients, consumers, and scientific stakeholders.&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Session I: A Robust Sentinel System for the 21st Century&lt;/strong&gt;&lt;br&gt;
Objective: In response to new legislative mandates and the desire to diversify scientific expertise and enhance core key capabilities in the Sentinel System, the Center for Drug Evaluation and Research (CDER) has awarded a new five-year contract that establishes a new organizational structure for the Sentinel Coordinating Center. This new contract builds on FDA successes integrating the active, post-market safety surveillance into regulatory decision-making. This session will feature key leads from each Sentinel coordinating center who will discuss plans on how to advance and transform Sentinel’s data infrastructure into a national resource for evidence generation. Panelists will also discuss opportunities for collaboration to broaden stakeholder involvement, improve access to new data sources and analytic tools, and ensure more efficient and effective safety surveillance activities.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Session II: Building the BEST Network and Establishing New Capabilities for the Surveillance of Biologics&lt;/strong&gt;&lt;br&gt;
Objective: Launched in 2017, the BEST Initiative enacts the Agency’s mandate to implement active surveillance for biologic products. This session will highlight key achievements of BEST over the last year enhancing its capabilities to execute safety and effectiveness surveillance and inform regulatory decision making. CBER representatives will discuss ongoing work to support the expansion of the BEST data network and methods infrastructure as well as specific studies utilizing the infrastructure.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Session III: Leveraging the Sentinel Initiative for COVID-19&lt;/strong&gt;&lt;br&gt;
Objective: The U.S. FDA’s Sentinel Initiative is engaged in numerous activities to protect and promote public health during the COVID-19 pandemic. This session will highlight key ongoing efforts across CDER and CBER to leverage Sentinel data infrastructure to describe course of illness, and evaluate the utilization, safety, and effectiveness of available COVID-19 therapeutics and vaccines under real-world conditions.&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>2020 Pfizer/ASA/UConn Distinguished Statistician Colloquium: From the Application to the General – Notation is Everything</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/202010142020-pfizer-asa-uconn-distinguished-statistician-colloquium-from-the-application-to-the-general-notation-is-everything/</link>
      <pubDate>Wed, 14 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/202010142020-pfizer-asa-uconn-distinguished-statistician-colloquium-from-the-application-to-the-general-notation-is-everything/</guid>
      <description></description>
    </item>
    
    <item>
      <title>R in Pharma</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20201013r-in-pharma/</link>
      <pubDate>Tue, 13 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20201013r-in-pharma/</guid>
      <description>&lt;p&gt;The 2020 R/Pharma conference was held as a virtual event between October 13th and 15th October. Over 1000 people from 26 countries registered for the main conference. In addition, 11 workshops were held the week before the conference.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Protecting confidentiality and privacy in clinical trial and medical data sets</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201007protecting-confidentiality-and-privacy-in-clinical-trial-and-medical-data-sets/</link>
      <pubDate>Wed, 07 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201007protecting-confidentiality-and-privacy-in-clinical-trial-and-medical-data-sets/</guid>
      <description>&lt;p&gt;We are increasingly living in a data driven world. Data are collected in many different ways for a variety of purposes. As such concerns around protecting the privacy of individuals have increased in recent times. Research into protecting the confidentiality of any data collected is an important and challenging area of research. In particular, there is often a trade-off between protecting confidentiality and preserving the utility in the data. This meeting seeks to explore and address issues of protecting confidentiality and privacy when it comes to collecting clinical trial and medical/health data. The session speakers comprise some of the world leaders and experts in the field bringing together researchers from both academia and the pharmaceutical industry.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Randomization and Regression Adjustment</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201007randomization-and-regression-adjustment/</link>
      <pubDate>Wed, 07 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201007randomization-and-regression-adjustment/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Cytel’s New Horizons Webinar Series</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20201005cytel-s-new-horizons-webinar-series/</link>
      <pubDate>Mon, 05 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20201005cytel-s-new-horizons-webinar-series/</guid>
      <description>&lt;p&gt;&lt;span style=&#34;color: green;&#34;&gt;&lt;em&gt;Replay links available&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Increasing the Power of Platform Trials: Efficient Multi-Arm Multi-Stage Adaptive Designs&lt;/strong&gt;&lt;br&gt;
Speaker: Cyrus Mehta&lt;br&gt;
October 5, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2713671&amp;amp;sessionid=1&amp;amp;key=DEC35F5F99E3B346CD3428FB63E00EA1&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;The Value of Detailed Statistical Trial Simulations – A Case Study for Rare Diseases&lt;/strong&gt;&lt;br&gt;
Speaker: Ursula Garczarek&lt;br&gt;
October 26, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2754403&amp;amp;sessionid=1&amp;amp;key=5190486304A26AF8A168A9EB5762E412&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Key Design Considerations for Adaptive Platform Trials&lt;/strong&gt;&lt;br&gt;
Speaker: Jay Park&lt;br&gt;
November 2, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2803072&amp;amp;sessionid=1&amp;amp;key=B00AA58DD8F16FD72214ED83EAE3F56C&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;AI in Clinical Research: Prediction and Causal Inference&lt;/strong&gt;&lt;br&gt;
Speaker: Alind Gupta&lt;br&gt;
November 9, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2803079&amp;amp;sessionid=1&amp;amp;key=F30F710608E4E55C3E02D0193E42FEAB&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>A New Measurements-based Approach to Machine Learning for Bioinformatics</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201002a-new-measurements-based-approach-to-machine-learning-for-bioinformatics/</link>
      <pubDate>Fri, 02 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201002a-new-measurements-based-approach-to-machine-learning-for-bioinformatics/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Annual Real World Evidence Conference: Applying Lessons Learned from RWE in the Time of COVID-19 to the Future</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20201001annual-real-world-evidence-conference-applying-lessons-learned-from-rwe-in-the-time-of-covid-19-to-the-future/</link>
      <pubDate>Thu, 01 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20201001annual-real-world-evidence-conference-applying-lessons-learned-from-rwe-in-the-time-of-covid-19-to-the-future/</guid>
      <description>&lt;p&gt;COVID-19 has disrupted the evidence-generation paradigm, resulting in the expanded use of novel technologies, data, and evidence. These new advancements not only improve clinical care and medical product development to fight the pandemic, but also have the potential to inform the future of drug development more broadly. This meeting will explore how COVID-19 has accelerated decision-maker understanding and use of real-world data (RWD) and real-world evidence (RWE) and its application in a post-COVID-19 environment.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Detangle modern dose-finding designs: A tutorial</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201001detangle-modern-dose-finding-designs-a-tutorial/</link>
      <pubDate>Thu, 01 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201001detangle-modern-dose-finding-designs-a-tutorial/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Advancing Early Stage Oncology Research with Adaptive Designs and Master Protocols</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200929advancing-early-stage-oncology-research-with-adaptive-designs-and-master-protocols/</link>
      <pubDate>Tue, 29 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200929advancing-early-stage-oncology-research-with-adaptive-designs-and-master-protocols/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;Improved determination of the maximum tolerated dose, comparing different designs for dose selection&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Advantages of basket trial design for finding the most appropriate indication(s)&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Current regulatory positions and outlook of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human use (ICH)&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Operational implications of different designs&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Under the Hood of 1Point3Acres COVID-19 Map and Tracker</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200925under-the-hood-of-1point3acres-covid-19-map-and-tracker/</link>
      <pubDate>Fri, 25 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200925under-the-hood-of-1point3acres-covid-19-map-and-tracker/</guid>
      <description>&lt;p&gt;In this talk, Yu will first discuss how her volunteer team fought to have brought data transparency to CovidNet. Then, Kyle will present his team’s novel approach to continuous data quality monitoring, which combines semantic analysis with time series anomaly detection methods, ending with some examples showing issues (known and benign) detected in the 1point3acres dataset. Prof Shan Lu will also provide an example how the high quality data source can be highly useful for even non-biological scientists to produce meaningful analysis in a situation like COVID-19 pandemic.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop 2020</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20200922asa-biopharmaceutical-section-regulatory-industry-statistics-workshop-2020/</link>
      <pubDate>Tue, 22 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20200922asa-biopharmaceutical-section-regulatory-industry-statistics-workshop-2020/</guid>
      <description>&lt;p&gt;The ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop is sponsored by the ASA Biopharmaceutical Section in cooperation with the FDA Statistical Association. The conference lasts two days each year, with invited sessions co-chaired by statisticians from industry, academia, and the FDA. In addition, short courses on related topics are offered the day prior to the workshop.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Study Design Considerations and an Update on the Pilot Investigation in Cancer</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200922study-design-considerations-and-an-update-on-the-pilot-investigation-in-cancer/</link>
      <pubDate>Tue, 22 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200922study-design-considerations-and-an-update-on-the-pilot-investigation-in-cancer/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Companion Diagnostics and Clinical Development in Oncology: A Statistical Perspective</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200917companion-diagnostics-and-clinical-development-in-oncology-a-statistical-perspective/</link>
      <pubDate>Thu, 17 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200917companion-diagnostics-and-clinical-development-in-oncology-a-statistical-perspective/</guid>
      <description>&lt;p&gt;This webinar provided a discussion around the need for integration of biomarker and IVD validation in clinical development, with a focus in oncology and companion diagnostics. It highlighted how flawed analytical and/or clinical validation can jeopardize a biomarker’s and drug’s clinical utility and showcase why biomarkers deserved statistical rigor throughout the development and validation process.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>NISS/Merck Meetup: Challenges and Potential in Vaccine Development</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200917niss-merck-meetup-challenges-and-potential-in-vaccine-development/</link>
      <pubDate>Thu, 17 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200917niss-merck-meetup-challenges-and-potential-in-vaccine-development/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Extending A Trial’s Design – Case Studies of Dealing with Study Design Issues</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200916extending-a-trial-s-design-case-studies-of-dealing-with-study-design-issues/</link>
      <pubDate>Wed, 16 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200916extending-a-trial-s-design-case-studies-of-dealing-with-study-design-issues/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Non-proportional Hazards&lt;/strong&gt; &lt;br&gt;
Non-proportional hazards and complex survival curves have become of increasing interest, due to being commonly seen in immunotherapy development. This has led to interest in assessing the robustness of standard methods and alternative methods that better adapt to deviations. In this webinar, we look at methods proposed for complex survival curves and the weighted log-rank test as a candidate model to deal with a delayed survival effect.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Cluster Randomization&lt;/strong&gt;&lt;br&gt;
Cluster-randomized designs are often adopted when there is a high risk of contamination if cluster members were randomized individually. Stepped-wedge designs are useful in cases where it is difficult to apply a particular treatment to half of the clusters at the same time. In this webinar, we introduce cluster randomization and stepped-wedge designs to provide an insight into the requirements of more complex randomization schedules.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;hree Armed Trials&lt;/strong&gt;&lt;br&gt;
Non-inferiority testing is a common hypothesis test in the development of generic medicine and medical devices. The most common design compares the proposed non-inferior treatment to the standard treatment alone but this leaves uncertain if the treatment effect is the same as from previous studies. This “assay sensitivity” problem can be resolved by using a three-arm trial which includes placebo alongside the new and reference treatments for direct comparison.  In this webinar we show a complete testing approach to this gold standard design and how to find the appropriate allocation and sample size for this study.&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>PSI Journal Club: Longitudinal Data</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200916psi-journal-club-longitudinal-data/</link>
      <pubDate>Wed, 16 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200916psi-journal-club-longitudinal-data/</guid>
      <description>&lt;p&gt;Two papers were discussed:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;Sebastian Häckl, Armin Koch &amp;amp; Florian Lasch, &lt;a href=&#34;https://nam03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1002%2Fpst.1964&amp;amp;data=02%7C01%7Cpgokani%40amgen.com%7Cdb5d7738508f4769529708d84b2a54b7%7C4b4266a6136841afad5a59eb634f7ad8%7C0%7C0%7C637341992474201251&amp;amp;sdata=pLqJ8FoEEvKGIim4yecClhu92Ck4hzpJgUTLEms%2BcUw%3D&amp;amp;reserved=0&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;strong&gt;Empirical evaluation of the implementation of the EMA guideline on missing data in confirmatory clinical trials: Specification of mixed models for longitudinal data in study protocols&lt;/strong&gt;&lt;/a&gt;, &lt;em&gt;Pharmaceutical Statistics, 2019; volume 18, Issue 6, Pages 636-644&lt;/em&gt;.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Mutamba T. Kayembe, Shahab Jolani, Frans E. S. Tan &amp;amp; Gerard J. P. van Breukelen, &lt;a href=&#34;https://nam03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1002%2Fpst.2041&amp;amp;data=02%7C01%7Cpgokani%40amgen.com%7Cdc9b7a71ede4491b426608d835372414%7C4b4266a6136841afad5a59eb634f7ad8%7C0%7C0%7C637317858232667163&amp;amp;sdata=zIb4UKtm%2FQq8jCsOf6YPYtaWGo8iSv4nV6WJ62vj0I4%3D&amp;amp;reserved=0&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;strong&gt;Imputation of missing covariate in randomized controlled trials with a continuous outcome: Scoping review and new results&lt;/strong&gt;&lt;/a&gt;, &lt;em&gt;Pharmaceutical Statistics, 2020; volume 19, Issue 6, Pages 840-860&lt;/em&gt;.&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Statistical Optimization Methods for Machine Learning</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200915statistical-optimization-methods-for-machine-learning/</link>
      <pubDate>Tue, 15 Sep 2020 12:00:00 -0800</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200915statistical-optimization-methods-for-machine-learning/</guid>
      <description>&lt;p&gt;Statistics and optimization are two of the foundational pillars of machine learning, and it is well recognized that optimization provides powerful tools for statistics. In recent years, techniques of the complementary nature, i.e., using statistics to improve optimization algorithms, have become increasingly successful. In this talk, we present several recent works on such statistical optimization methods. First, we discuss how to use statistical hypothesis testing to automatically adjust the learning rate of stochastic gradient methods in training deep neural networks. Then we overview some recent advances in structured nonconvex optimization using stochastic variance reduction techniques. Finally we will briefly explain how to leverage statistical preconditioning to accelerate distributed optimization.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>How Health-Related Social Media Can Complement Traditional RWE Approaches to Access Unique Patient Insights</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200903how-health-related-social-media-can-complement-traditional-rwe-approaches-to-access-unique-patient-insights/</link>
      <pubDate>Thu, 03 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200903how-health-related-social-media-can-complement-traditional-rwe-approaches-to-access-unique-patient-insights/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;Examples of health-related social media data sources&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;The ethical considerations of using these data&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;When it is beneficial to use health-related social media as a real-world data source&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Some methods used to generate insights from these data&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Types of messages that can be generated from these data&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Scaling Data Science at Your Organization (Part 3)</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200903scaling-data-science-at-your-organization-part-3/</link>
      <pubDate>Thu, 03 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200903scaling-data-science-at-your-organization-part-3/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Using R to Drive Agility in Clinical Reporting</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200903using-r-to-drive-agility-in-clinical-reporting/</link>
      <pubDate>Thu, 03 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200903using-r-to-drive-agility-in-clinical-reporting/</guid>
      <description>&lt;p&gt;The R language is used extensively throughout the pharmaceutical industry. But its use within the tightly regulated clinical reporting workflows has remained limited. GSK Biostatistics has embarked upon a journey to embed R as a primary statistical analysis tool for clinical reporting.&lt;/p&gt;
&lt;p&gt;Enabling R within a global department of over 600 Statisticians, Programmers and Data Scientists is challenging! It requires planning, patience, and a strong foundation that enables consistency across the enterprise. We invite you to learn more about how we achieved this at GSK.&lt;/p&gt;
&lt;p&gt;You&amp;rsquo;ll learn about our tidyverse-centric training program, a future-ready Working Area for R Programming (WARP) environment, and a leading-edge R for Clinical Reporting (R4CR) initiative. The goal: help embed R in every-day clinical reporting output.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>On Nearly Assumption-Free Tests of Nominal Confidence Interval Coverage for Causal Parameters Estimated by Machine Learning</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200901on-nearly-assumption-free-tests-of-nominal-confidence-interval-coverage-for-causal-parameters-estimated-by-machine-learning/</link>
      <pubDate>Tue, 01 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200901on-nearly-assumption-free-tests-of-nominal-confidence-interval-coverage-for-causal-parameters-estimated-by-machine-learning/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Data Science Conference on COVID-19</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20200828data-science-conference-on-covid-19/</link>
      <pubDate>Fri, 28 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20200828data-science-conference-on-covid-19/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Demystifying “Drop-Out” in Single Cell RNA-seq</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200828demystifying-drop-out-in-single-cell-rna-seq/</link>
      <pubDate>Fri, 28 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200828demystifying-drop-out-in-single-cell-rna-seq/</guid>
      <description>&lt;p&gt;Droplet-based single-cell RNA-sequencing (scRNA-seq) methods have changed the landscape of genomics research in complex biological systems by producing single cell resolution data at affordable costs. In the state-of-the-arts protocols, a step called barcoding unique molecular identifiers (UMI) has been introduced to remove amplification bias and further improve data quality. Recent literature suggests that barcoding has led to a different error structure in the count data with much less technical noise. Regardless, many tools do not acknowledge the differences between the read count data and UMI count data, still assuming that both suffer from excessive technical noise. In this presentation, I will make a brief overview of scRNA-seq data analysis pipelines and then present extensive analyses of publicly available UMI data sets that challenge the assumptions of most existing pre-processing tools. Our results suggest that resolving cell-type heterogeneity should be the foremost step of the scRNA-seq analysis pipeline. Normalizing or imputing the data set before resolving the heterogeneity can lead to adversary consequences in downstream analysis. As a result, we provide a new perspective on scRNA-seq data analysis by fully integrating pre-processing and clustering, which was classified as part of the downstream analysis. The proposed procedures have been implemented in software, HIPPO. If time permits, I will also talk about other single cell analysis tools developed in my group, VIPER, an imputation method for SMART-seq data, and dmatch, an alignment tool for multiple scRNA-seq samples batch correction.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Purdue University: Deep Learning Methods and Theory Webinar Series</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200828purdue-university-deep-learning-methods-and-theory-webinar-series/</link>
      <pubDate>Fri, 28 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200828purdue-university-deep-learning-methods-and-theory-webinar-series/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;August 28, &lt;strong&gt;Intuitive Introduction to Deep Learning&lt;/strong&gt;, Professor Lawrence Carin, &lt;a href=&#34;https://www.youtube.com/watch?v=sVca43PstWA&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;strong&gt;Video&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;September 4, &lt;strong&gt;Distributed Machine Learning&lt;/strong&gt;, Professor Heng Huang,  &lt;a href=&#34;https://www.youtube.com/watch?v=5fFg4SLq4mU&amp;amp;t=10s&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;strong&gt;Video&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;September 11, &lt;strong&gt;A Representational Model of Grid Cells Based on Matrix Lie Algebras&lt;/strong&gt;, Professor Ying Nian Wu, &lt;a href=&#34;https://www.youtube.com/watch?v=lYQElUIaqEw&amp;amp;t=12s&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;strong&gt;Video&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;September 18, &lt;strong&gt;Integrating Domain-Knowledge into Deep Learning&lt;/strong&gt;, Professor Ruslan Salakhutdinov, &lt;a href=&#34;https://www.youtube.com/watch?v=gE78sONx_-k&amp;amp;t=4s&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;&lt;strong&gt;Video&lt;/strong&gt;&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Scaling Data Science at Your Organization (Part 2)</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200827scaling-data-science-at-your-organization-part-2/</link>
      <pubDate>Thu, 27 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200827scaling-data-science-at-your-organization-part-2/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Debunking the R vs. Python Myth</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200826debunking-the-r-vs-python-myth/</link>
      <pubDate>Wed, 26 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200826debunking-the-r-vs-python-myth/</guid>
      <description>&lt;p&gt;How many times have you heard the phrase “X is better than Y for data science”? This is a very common misconception among data scientists, and a very broad definition of data science as a whole. For data science to be impactful, it needs to be credible, agile, and durable. To be able to do this, we need to embrace the differences between R vs. Python. Maybe you prefer R for data wrangling and Python for modeling - that’s great! Why should serious data science be stifled for the sake of language loyalty? Data science teams need to use the wealth of tools available to them to deliver the most impactful results. This webinar will be a discussion among data science leaders, debunking this common myth.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Designing Clinical Trials from a Program Perspective</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200826designing-clinical-trials-from-a-program-perspective/</link>
      <pubDate>Wed, 26 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200826designing-clinical-trials-from-a-program-perspective/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Almost Matching Exactly</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200825almost-matching-exactly/</link>
      <pubDate>Tue, 25 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200825almost-matching-exactly/</guid>
      <description>&lt;p&gt;We will present a matching framework for causal inference in the potential outcomes setting called Almost Matching Exactly. In this setting, the goal is to match treatment and control units on as many covariates as possible. We use machine learning on a hold-out training set to learn which variables are more important to match on; in essence, the method learns a distance metric for matching. This way, our methods retain the interpretability of matching, but also use distance metrics that are automated rather than being hand-designed, and are adaptive to the data rather than being fixed. The key constraint is that units are always matched on a set of covariates that together can predict the outcome well. Our techniques for discrete variables are called Fast Large-Scale Almost Matching Exactly (FLAME), Dynamic Almost Matching Exactly (DAME), Matching After Learning to Stretch (MALTS), and Adaptive Hyper-boxes. FLAME and DAME match units on a weighted Hamming distance for discrete variables using techniques that are natural for query processing in database management. FLAME rapidly produces high quality matched groups for discrete data, even for datasets that are too large to fit in memory. DAME produces higher quality matched groups than FLAME, but is slower. MALTS is useful for continuous variables and learns distance metrics that stretch the covariates in an interpretable way. Adaptive hyper-boxes can gracefully handle both discrete and continuous covariates flexibly and interpretably by optimizing a box around each treatment unit. These methods rival black box machine learning methods in their estimation accuracy but have the benefit of being interpretable and easier to troubleshoot.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Scaling Data Science at Your Organization (Part 1)</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200820scaling-data-science-at-your-organization-part-1/</link>
      <pubDate>Thu, 20 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200820scaling-data-science-at-your-organization-part-1/</guid>
      <description>&lt;p&gt;IPTOP framework (Infrastructure, People, Tools, Organization and Processes) for building data strategies and systematically scaling data science within an organization&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Duke-Margolis: Data Sharing to Accelerate Therapeutic Development for Rare Diseases (Day 2)</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200819duke-margolis-data-sharing-to-accelerate-therapeutic-development-for-rare-diseases-day-2/</link>
      <pubDate>Wed, 19 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200819duke-margolis-data-sharing-to-accelerate-therapeutic-development-for-rare-diseases-day-2/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Adaptive Designs for Phase II Clinical Trials </title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200818adaptive-designs-for-phase-ii-clinical-trials/</link>
      <pubDate>Tue, 18 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200818adaptive-designs-for-phase-ii-clinical-trials/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;Important aspects of Phase II trials designs to consider&lt;/li&gt;
&lt;li&gt;Practical worked examples of&lt;/li&gt;
&lt;li&gt;MCP-Mod (continuous outcome)&lt;/li&gt;
&lt;li&gt;MCP-Mod (binary outcome)&lt;/li&gt;
&lt;li&gt;Fleming GST (binary outcome)&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Duke-Margolis: Data Sharing to Accelerate Therapeutic Development for Rare Diseases (Day 1)</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200818duke-margolis-data-sharing-to-accelerate-therapeutic-development-for-rare-diseases-day-1/</link>
      <pubDate>Tue, 18 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200818duke-margolis-data-sharing-to-accelerate-therapeutic-development-for-rare-diseases-day-1/</guid>
      <description></description>
    </item>
    
    <item>
      <title> testthat 3.0.0</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200813testthat-3-0-0/</link>
      <pubDate>Thu, 13 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200813testthat-3-0-0/</guid>
      <description>&lt;p&gt;In this webinar, I&amp;rsquo;ll introduce some of the major changes coming in testthat 3.0.0. The biggest new idea in testthat 3.0.0 is the idea of an edition. You must deliberately choose to use the 3rd edition, which allows us to make breaking changes without breaking old packages. testthat 3e deprecates a number of older functions that we no longer believe are a good idea, and tweaks the behaviour of expect_equal() and expect_identical() to give considerably more informative output (using the new waldo package).&lt;/p&gt;
&lt;p&gt;testthat 3e also introduces the idea of snapshot tests which record expected value in external files, rather than in code. This makes them particularly well suited to testing user output and complex objects. I&amp;rsquo;ll show off the main advantages of snapshot testing, and why it&amp;rsquo;s better than our previous approaches of verify_output() and expect_known_output().&lt;/p&gt;
&lt;p&gt;Finally, I&amp;rsquo;ll go over a bunch of smaller quality-of-life improvements, including tweaks to test reporting and improvements to expect_error(), expect_warning() and expect_message().&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Estimands: Not Just a Statistical Issue</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200813estimands-not-just-a-statistical-issue/</link>
      <pubDate>Thu, 13 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200813estimands-not-just-a-statistical-issue/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Adaptive and Bayesian Designs for Dose-Finding</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200805adaptive-and-bayesian-designs-for-dose-finding/</link>
      <pubDate>Wed, 05 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200805adaptive-and-bayesian-designs-for-dose-finding/</guid>
      <description>&lt;p&gt;Finding the right dose in Phase 2 gives a potential new therapy its best chance to demonstrate efficacy during Phase 3. A well-executed dose-ranging trial therefore has the potential to alter the course of the entire clinical development program. This webinar demonstrates how adaptive and Bayesian techniques can be implemented for optimal dose-finding.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>100 Stories of Causal Inference</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200804100-stories-of-causal-inference/</link>
      <pubDate>Tue, 04 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200804100-stories-of-causal-inference/</guid>
      <description>&lt;p&gt;In social science we learn from stories.  The best stories are anomalous and immutable.  We shall briefly discuss the theory of stories, the paradoxical nature of how we learn from them, and how this relates to forward and reverse causal inference.  Then we will go through some stories of applied causal inference and see what lessons we can draw from them.  We hope this talk will be useful as a model for how you can better learn from own experiences as participants and consumers of causal inference.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Navigating US FDA Initiatives to Expedite Development, Approval, and Emergency Access to COVID-19 Treatments</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200730navigating-us-fda-initiatives-to-expedite-development-approval-and-emergency-access-to-covid-19-treatments/</link>
      <pubDate>Thu, 30 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200730navigating-us-fda-initiatives-to-expedite-development-approval-and-emergency-access-to-covid-19-treatments/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;An overview of the Coronavirus Treatment Acceleration Program (CTAP)&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;The Emergency Use Authorization (EUA) and single patient expanded access pathways and processes&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Securing meetings with the FDA for COVID-19 programs&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Key clinical development guidances specific to COVID-19 programs&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Ingram Olkin Forum: Unplanned Disruptions in Clinical Trials (Day 2)</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200729ingram-olkin-forum-unplanned-disruptions-in-clinical-trials-day-2/</link>
      <pubDate>Wed, 29 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200729ingram-olkin-forum-unplanned-disruptions-in-clinical-trials-day-2/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Design and Data Source Considerations from Pilot Investigations in Cardiovascular Disease</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200728design-and-data-source-considerations-from-pilot-investigations-in-cardiovascular-disease/</link>
      <pubDate>Tue, 28 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200728design-and-data-source-considerations-from-pilot-investigations-in-cardiovascular-disease/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Enabling Remote Data Science Teams</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200728enabling-remote-data-science-teams/</link>
      <pubDate>Tue, 28 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200728enabling-remote-data-science-teams/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;Setting up a remote and collaborative R environment&lt;/li&gt;
&lt;li&gt;Version control and Scrum&lt;/li&gt;
&lt;li&gt;Using Shiny and RStudio Connect to share apps within and across teams&lt;/li&gt;
&lt;li&gt;How to improve the UI and appearance of Shiny dashboards&lt;/li&gt;
&lt;li&gt;How to scale Shiny dashboards to hundreds of users&lt;/li&gt;
&lt;li&gt;How to build and grow a remote data science team&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Flexible Clinical Trial Design - Survival, Stepped-Wedge &amp; MAMS Designs</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200723flexible-clinical-trial-design-survival-stepped-wedge-mams-designs/</link>
      <pubDate>Thu, 23 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200723flexible-clinical-trial-design-survival-stepped-wedge-mams-designs/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Flexible Survival Analysis Designs&lt;/strong&gt;&lt;br&gt;
Non-proportional hazards and other complex survival curves have become of increasing interest, due to being commonly seen in immunotherapy development. This has led to interest in assessing the robustness of standard methods and alternative methods that better adapt to deviations.&lt;/p&gt;
&lt;p&gt;In this webinar, we will look at power analysis assuming complex survival curves and the weighted log-rank test as one candidate model to deal with a delayed survival effect.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Stepped-Wedge designs&lt;/strong&gt;&lt;br&gt;
Cluster-randomized designs are often adopted when there is a high risk of contamination if cluster members were randomized individually. Stepped-wedge designs are useful in cases where it is difficult to apply a particular treatment to half of the clusters at the same time.&lt;/p&gt;
&lt;p&gt;In this webinar, we will introduce stepped-wedge designs and provide an insight into the more complex, flexible randomization schedules available.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Multi-Arm Multi-Stage (MAMS)&lt;/strong&gt;&lt;br&gt;
MAMs designs provide the ability to assess more treatments in less time than could be done with a series of two-arm trials and can offer smaller sample size requirements when compared to that required for the equivalent number of two-arm trials.&lt;/p&gt;
&lt;p&gt;In this webinar, we will look at the design of a Group Sequential MAMS design and explore its design requirements.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Ingram Olkin Forum: Unplanned Disruptions in Clinical Trials (Day 1)</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200721ingram-olkin-forum-unplanned-disruptions-in-clinical-trials/</link>
      <pubDate>Tue, 21 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200721ingram-olkin-forum-unplanned-disruptions-in-clinical-trials/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Using Multiple Natural Experimental Designs to Triangulate the Impact of a Policy Change</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200717dahshu/</link>
      <pubDate>Fri, 17 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200717dahshu/</guid>
      <description>&lt;p&gt;Estimating causal effects is best done using randomized controlled trials. Regrettably, for many policy-relevant questions only observational data are available. In this talk we explore how (i) decomposing a policy into multiple parts, and (ii) leveraging multiple study designs can produce stronger, more defensible causal estimates.&lt;br&gt;
We explore these statistical concepts through an example from health outcomes research: The feasibility and effectiveness of delaying surgery to transfer patients with acute type A aortic dissection—a catastrophic disease that requires prompt intervention—to higher-volume aortic surgery hospitals is unknown. We investigated the hypothesis that regionalizing care at high-volume hospitals for acute type A aortic dissections will lower mortality. We decomposed this hypothesis into subparts, investigating the isolated effect of transfer and the isolated effect of receiving care at a high-volume versus a low-volume facility. We used a preference-based instrumental variable design to address unmeasured confounding and matching to separate the effect of transfer from volume. We used the carefully deployed instrumental variable design, and contrast it with a decomposed propensity score study design, to gain deeper insights into the elements giving rise to confounding. We also develop a simple, but complete, form of sensitivity analysis to bound the effect of censored observations.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Estimands and Analysis Considerations for Clinical Trials Impacted by COVID-19</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200716estimands-and-analysis-considerations-for-clinical-trials-impacted-by-covid-19/</link>
      <pubDate>Thu, 16 Jul 2020 08:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200716estimands-and-analysis-considerations-for-clinical-trials-impacted-by-covid-19/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;The use of the estimand framework to assess and address pandemic-related disruptions&lt;/li&gt;
&lt;li&gt;Analysis strategies for pandemic-related missing and unobservable values&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Introduction to Population Enrichment Trial Designs</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200715introduction-to-population-enrichment-trial-designs/</link>
      <pubDate>Wed, 15 Jul 2020 08:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200715introduction-to-population-enrichment-trial-designs/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Good Statistical Practices to Tackle the Lack of Reproducibility in Preclinical Research</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200715good-statistical-practices-to-tackle-the-lack-of-reproducibility-in-preclinical-research/</link>
      <pubDate>Wed, 15 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200715good-statistical-practices-to-tackle-the-lack-of-reproducibility-in-preclinical-research/</guid>
      <description>&lt;p&gt;4 key learnings attendees will take away from this webinar:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;The value of good design of experiments&lt;/li&gt;
&lt;li&gt;Consider Bayesian statistics to answer your question&lt;/li&gt;
&lt;li&gt;P-values is not always what you’re looking for&lt;/li&gt;
&lt;li&gt;Adopt a life-cycle over the long-run, not just study by study&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Avoid Dashboard Fatigue</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200714avoid-dashboard-fatigue/</link>
      <pubDate>Tue, 14 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200714avoid-dashboard-fatigue/</guid>
      <description>&lt;p&gt;In this webinar, we’ll show you an easy way teams can solve these problems using proactive email notifications through the blastula and gt packages, and how RStudio pro products can be used to scale out those solutions for enterprise applications. Dynamic emails are a powerful way to meet decision makers where they live - their inbox - while displaying exactly the results needed to influence decision-making. Best of all, these notifications are crafted with code, ensuring your work is still reproducible, durable, and credible.&lt;/p&gt;
&lt;p&gt;We’ll demonstrate how this approach provides solutions for data quality monitoring, detecting and alerting on anomalies, and can even automate routine (but precisely formatted) KPI reporting.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Duke MArgolis: Establishing a High-Quality Real-World Data Ecosystem</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20200713duke-margolis-establishing-a-high-quality-real-world-data-ecosystem/</link>
      <pubDate>Mon, 13 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20200713duke-margolis-establishing-a-high-quality-real-world-data-ecosystem/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.youtube.com/watch?v=EqffCIVzFt0&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Day 1 video&lt;/a&gt;; &lt;a href=&#34;https://www.youtube.com/watch?v=Qm-qD8DTgOE&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Day 2 video&lt;/a&gt;&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Clinical Endpoints and Treatment Effect in Immuno-Oncology</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200707clinical-endpoints-and-treatment-effect-in-immuno-oncology/</link>
      <pubDate>Tue, 07 Jul 2020 11:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200707clinical-endpoints-and-treatment-effect-in-immuno-oncology/</guid>
      <description>&lt;p&gt;In this webinar the speakers reviewed:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;Adaptations to tumor response and progression criteria for immune therapies. Survival may be the endpoint of choice for clinical trials in some tumor types, but presence of delayed treatment effects and non-proportional hazards may complicate evaluation of treatment benefits.&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Statistical methods to best describe and test for treatment effects in immuno-oncology randomized clinical trials.&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Causal Inference in the Light of Drug Repurposing for SARS-CoV-2</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200707causal-inference-in-the-light-of-drug-repurposing-for-sars-cov-2/</link>
      <pubDate>Tue, 07 Jul 2020 08:30:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200707causal-inference-in-the-light-of-drug-repurposing-for-sars-cov-2/</guid>
      <description>&lt;p&gt;Massive data collection holds the promise of a better understanding of complex phenomena and ultimately, of better decisions. An exciting opportunity in this regard stems from the growing availability of perturbation / intervention data (drugs, knockouts, overexpression, etc.) in biology. In order to obtain mechanistic insights from such data, a major challenge is the development of a framework that integrates observational and interventional data and allows predicting the effect of yet unseen interventions or transporting the effect of interventions observed in one context to another. I will present a framework for causal structure discovery based on such data and characterize the causal relationships that are identifiable in this setting. We end by demonstrating how these ideas can be applied for drug repurposing in the current SARS-CoV-2 crisis.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>The Time for Causal Inference is Now</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200707the-time-for-causal-inference-is-now/</link>
      <pubDate>Tue, 07 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200707the-time-for-causal-inference-is-now/</guid>
      <description></description>
    </item>
    
    <item>
      <title>MCP-Mod: Optimizing Phase II Dose Selection for Continuous and Non-Continuous Endpoints</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200617mcp-mod-optimizing-phase-ii-dose-selection-for-continuous-and-non-continuous-endpoints/</link>
      <pubDate>Wed, 17 Jun 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200617mcp-mod-optimizing-phase-ii-dose-selection-for-continuous-and-non-continuous-endpoints/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;An introduction to MCP-Mod&lt;/li&gt;
&lt;li&gt;Why use MCP-Mod for Phase II trials&lt;/li&gt;
&lt;li&gt;Steps to generate superior statistical evidence for dose-selection&lt;/li&gt;
&lt;li&gt;MCP-Mod for various endpoints, including: Continuous Endpoint, Binary Endpoint&lt;/li&gt;
&lt;li&gt;Poisson Rates&lt;/li&gt;
&lt;li&gt;Negative Binomial rates&lt;/li&gt;
&lt;li&gt;Worked examples &amp;amp; case studies&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>COVID-19: Pandemic Preparedness and Lessons Learned</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200610dia/</link>
      <pubDate>Wed, 10 Jun 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200610dia/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;An overview of how COVID-19 progressed&lt;/li&gt;
&lt;li&gt;How can pharmaceutical companies be better prepared? Should there be plans and clinical development strategies in place?&lt;/li&gt;
&lt;li&gt;How do we build resiliency? What steps could/should be implemented at various stages to ‘flatten the curve’?&lt;/li&gt;
&lt;li&gt;Vulnerable communities and minority populations are at a disadvantage. How do we address these health disparities?&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Replication and Evidence Factors in Observational Studies</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200602replication-and-evidence-factors-in-observational-studies/</link>
      <pubDate>Tue, 02 Jun 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200602replication-and-evidence-factors-in-observational-studies/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Estimands in Oncology - A Virtual Panel Discussion</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200524estimands-in-oncology-a-virtual-panel-discussion/</link>
      <pubDate>Sun, 24 May 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200524estimands-in-oncology-a-virtual-panel-discussion/</guid>
      <description></description>
    </item>
    
    <item>
      <title>ASA-JDS Webinar Series: Data Science in Action in Response to the Outbreak of COVID-19</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200417asa-jds-webinar-series-data-science-in-action-in-response-to-the-outbreak-of-covid-19/</link>
      <pubDate>Fri, 17 Apr 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200417asa-jds-webinar-series-data-science-in-action-in-response-to-the-outbreak-of-covid-19/</guid>
      <description>&lt;p&gt;&lt;span style=&#34;color: green;&#34;&gt;&lt;em&gt;Replay links available on website&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Curating a COVID-19 data repository and forecasting county-level death counts in the United States&lt;/strong&gt;&lt;br&gt;
07/24/2020,  Dr. Bin Yu, University of California, Berkeley&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;The COVID-19 Forecast Hub: using statistics and data science to support decision-making in a pandemic&lt;/strong&gt;&lt;br&gt;
07/17/2020, Dr. Nicholas Reich, University of Massachusetts, Amherst&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Semiparametric Bayesian inference for the transmission dynamics of COVID-19 with a state-space model&lt;/strong&gt;&lt;br&gt;
07/10/2020, Dr. Yuan Ji, University of Chicago&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;The opportunities and challenges of healthcare systems in the COVID-19 era&lt;/strong&gt;&lt;br&gt;
06/26/2020, Dr. Kimia Ghobadi, Johns Hopkins University&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;A statistical transmission model for COVID-19 outbreak with adjustment of external factors&lt;/strong&gt;&lt;br&gt;
06/19/2020, Dr. Yifan Zhu, Fred Hutchinson Cancer Research Center&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Statistics and modeling in response to COVID-19 at NIAID&lt;/strong&gt;&lt;br&gt;
06/12/2020, Dr. Dean Follmann, National Institute of Allergy and Infectious Diseases&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;A biostatistician&amp;rsquo;s encounter with COVID-19 in New York City&lt;/strong&gt;&lt;br&gt;
06/05/2020, Dr. Usha Govindarajulu, Icahn School of Medicine at Mount Sinai&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Can the reported COVID-19 data tell us the truth? Scrutinizing the data from the measurement error models perspective&lt;/strong&gt;&lt;br&gt;
05/29/2020, Dr. Grace Yi, University of Western Ontario&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Predictions, role of interventions and implications of a national lockdown on the COVID-19 outbreak in India&lt;/strong&gt;&lt;br&gt;
05/22/2020, COV-IND-19 Study Group ( (Dr. Bhramar Mukherjee, University of Michigan; Dr. Debashree Ray, Johns Hopkins University; Rupam Bhattacharyya, University of Michigan; and Maxwell Salvatore, University of Michigan)&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;COVID-19: Analytic studies and opportunities for outside of epidemiology&lt;/strong&gt;&lt;br&gt;
05/15/2020, Dr. David Corliss, Peace-Work&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Estimation of incubation period distribution of COVID-19 using disease onset forward time: A novel cross-sectional and forward follow-up study&lt;/strong&gt;&lt;br&gt;
05/08/2020, Dr. Jing Qin, National Institute of Allergy and Infectious Diseases (NIAID)&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;COVID19 US dashboard: Spatiotemporal dynamics, nowcasting and forecasting of COVID-19 in the United States&lt;/strong&gt;&lt;br&gt;
05/01/2020, Dr. Lily Wang, Iowa State University&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Tracking reproductivity of COVID-19 pandemic with varying coefficient epidemiological models&lt;/strong&gt;&lt;br&gt;
04/24/2020, Dr. Song Xi Chen, Peking University&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;An epidemiological forecast model to assess the effect of social distancing on flattening the coronavirus curve in the USA&lt;/strong&gt;&lt;br&gt;
04/17/2020, Dr. Peter X.K. Song University of Michigan&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>RStudio Conference 2020</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20200127rstudio-conference/</link>
      <pubDate>Mon, 27 Jan 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20200127rstudio-conference/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
